HOLA Intervention for Doctor-Patient Relationship in Cancer Care
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to improve the relationship between Latino/a cancer patients and their oncologists by enhancing trust and understanding, which can lead to better health outcomes. Oncologists will learn new communication skills that align with Latino/a cultural values to strengthen connections with their patients. This trial suits Latino/a individuals with advanced cancer who have previously undergone treatment. Participants must be able to communicate in English or Spanish. As an unphased trial, this study offers a unique opportunity to contribute to research that could improve communication and trust in healthcare settings.
What prior data suggests that the HOLA intervention is safe for improving doctor-patient relationships?
This trial tests the HOLA program to improve communication between doctors and Latino/a cancer patients. It is not a drug or medical procedure but a training program to enhance doctor-patient dialogue.
As a new communication method, the HOLA program lacks previous studies with concrete safety data. However, since it does not involve medication or medical procedures, it is expected to be very safe for patients.
The trial is labeled "Not Applicable," indicating it tests ideas or methods rather than physical treatments. This suggests minimal safety concerns, as the program poses no physical risk to participants. Prospective participants can feel confident that the focus is on enhancing doctor-patient interactions without medical risks.12345Why are researchers excited about this trial?
Researchers are excited about the HOLA intervention because it aims to enhance the doctor-patient relationship in cancer care, an area often overlooked in traditional treatment. Standard cancer care typically focuses on medical procedures and medication, but HOLA adds a fresh perspective by incorporating interactive training for oncologists. This intervention uses pre-recorded video vignettes and role-playing sessions to improve communication skills, which can lead to better patient outcomes and satisfaction. By fostering stronger connections between doctors and patients, HOLA has the potential to improve the overall care experience for cancer patients.
What evidence suggests that the HOLA intervention is effective for improving the doctor-patient relationship in cancer care?
This trial will evaluate the HOLA intervention, designed to enhance communication between oncologists and their patients. Research has shown that effective communication between doctors and patients can improve health outcomes as much as some medicines. Studies indicate that when doctors prioritize the patient's needs and concerns, satisfaction and understanding improve, especially among cancer patients. Latino/a cancer patients, in particular, often benefit from communication that respects their cultural values. Evidence suggests that improving this communication can build trust and enhance clarity. Overall, strengthening the doctor-patient relationship can lead to better care experiences and outcomes for cancer patients.678910
Who Is on the Research Team?
Ana Tergas, MPH, MD
Principal Investigator
Rutgers, The State University of New Jersey
Are You a Good Fit for This Trial?
This trial is for Latino/a adults with advanced or metastatic pancreatic, stomach, liver, lung, or gynecological cancer whose disease has worsened after at least one round of chemotherapy. Participants must be able to give informed consent.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Intervention
Oncologists participate in the HOLA intervention, which includes a one-hour interactive didactic session and a one-hour small group session with pre-recorded video vignettes and role-playing.
Follow-up
Participants are monitored for the feasibility, acceptability, and appropriateness of the intervention, as well as preliminary efficacy in improving therapeutic alliances.
What Are the Treatments Tested in This Trial?
Interventions
- HOLA Intervention
Trial Overview
The study tests the HOLA intervention—a program that trains oncologists in culturally sensitive communication skills to improve their relationships with Latino/a patients. Some doctors use HOLA; others provide usual care. The impact on doctor-patient relationships will be compared.
How Is the Trial Designed?
4
Treatment groups
Active Control
The HOLA intervention is aimed at oncologists and consists of a one hour interactive didactic session and a one-hour small group session. Pre-recorded video vignettes and role playing with a trained moderator will be incorporated both into the interactive group didactic session and the small group session.
We will pilot test the HOLA intervention with eight oncologists and 32 of their patients, half (n=16 patients) who are under the care of an oncologist who will be randomized to receive the TA intervention (n=4 oncologists), and half (n=16 patients) who are under the care of an oncologist (n=4 oncologists) who was randomized to usual care.
We will pilot test the HOLA intervention with eight oncologists and 32 of their patients, half (n=16 patients) who are under the care of an oncologist who will be randomized to receive the TA intervention (n=4 oncologists), and half (n=16 patients) who are under the care of an oncologist (n=4 oncologists) who was randomized to usual care.
We will pilot test the HOLA intervention with eight oncologists and 32 of their patients, half (n=16 patients) who are under the care of an oncologist who will be randomized to receive the TA intervention (n=4 oncologists), and half (n=16 patients) who are under the care of an oncologist (n=4 oncologists) who was randomized to usual care.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Rutgers, The State University of New Jersey
Lead Sponsor
Citations
Oncologic Home-Hospitalization Delivers a High-Quality and ...
No safety issues were detected to be highly satisfied with the OHH model, and 77% reported a positive impact on their QoL. At study end, 60% of ...
HOLA COVID-19 study focuses on disruption of ...
Our study is a cross-sectional survey of how hematology-oncology practices in Latin America have adapted during the COVID-19 pandemic. We are ...
a cross-sectional study among Latina breast cancer survivors ...
There is strong evidence that both patient engagement and shared decision making are associated with better patient outcomes, including greater ...
Effect of a Patient-Centered Communication Intervention ...
Among this cohort of 590 patients with advanced cancer (median survival, 5.4 months), 71% wanted to be told their LE, but only 17.6% recalled a prognostic ...
Comparing the Effectiveness of Two Interventions To ...
This study compares the effectiveness of interventions to improve the quality of life of breast cancer survivors and their partners.
Data
Data is a collection of discrete or continuous values that conveys information, describing the quantity, quality, fact, statistics, other basic units of ...
Data.gov Home - Data.gov
Here you will find data, tools, and resources to conduct research, develop web and mobile applications, design data visualizations, and more. 535,101 datasets ...
Data
The OECD data pillar gathers all OECD data outputs from trusted statistics or indicators to interactive tools, dashboards and statistical releases covering ...
UN System Data Commons
The UN System Data Commons platform integrates authoritative SDG data from across the UN System into a public repository with a user-friendly interface and ...
Data | Open Access Journal
Data is a peer-reviewed, open access journal on data in science, with the aim of enhancing data transparency and reusability. The journal publishes in two ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.